Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07118358

BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

Led by Biotronik, Inc. · Updated on 2026-04-06

325

Participants Needed

2

Research Sites

106 weeks

Total Duration

On this page

Sponsors

B

Biotronik, Inc.

Lead Sponsor

B

Biotronik SE & Co. KG

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this Investigational Device Exemption trial is to confirm the safety and performance of the LivIQ leadless pacemaker system, in patients with a Class I or II indication for ventricular pacing (VVI/VDD) according to applicable guidelines. An integrated atrioventricular synchrony sub-study (AVS) is specifically designed to evaluate the AVS performance of the LivIQ system.

CONDITIONS

Official Title

BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a Class I or Class II indication for ventricular pacing (VVI/VDD) according to applicable guidelines
  • Are 18 years of age or older at the time of consent
  • Able to understand the study and provide written informed consent
  • Willing and able to complete all study visits and requirements for the full follow-up period
Not Eligible

You will not qualify if you...

  • AV block with a ventricular escape rhythm of 30 bpm or less at time of consent (restriction removed after early safety phase)
  • Femoral venous or cardiac anatomy unsuitable for device implantation
  • Morbid obesity preventing device telemetry communication within 20 cm
  • Intolerance to dexamethasone acetate
  • Presence of other implanted devices that may interfere with the pacemaker or procedure
  • Allergy to the pacemaker materials or implant tools
  • Previous attempt at leadless pacemaker implantation
  • Existing pacemaker, ICD, CRT device, or previous lead extraction with leads left in heart (except temporary pacemakers)
  • CIED device extraction within 72 hours or signs of infection post-extraction
  • Planned ICD or CRT device implantation
  • Unstable angina or recent heart attack within 30 days
  • Life expectancy less than 12 months
  • Unable to tolerate urgent sternotomy
  • Planned right-sided heart intervention within 30 days after implant (except AV nodal ablation after safety phase)
  • Listed for or has received heart transplant or has left ventricular assist device
  • Participation in other conflicting clinical trials without prior approval
  • Unable to attend planned or urgent study visits
  • Pregnant or planning pregnancy during the study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Kokura Memorial Hospita

Kitakyushu, Fukuoka, Japan, 802-8555

Actively Recruiting

2

National Cerebral and Cardiovascular Center Hospital

Suita, Osaka, Japan, 564-8565

Actively Recruiting

Loading map...

Research Team

J

Jennifer Alkire Project Manager

CONTACT

A

Andreas Peth Clinical Project Manager

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here